Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Licenses Knockout Mouse Technology to Lilly

NEW York, Nov. 16 – Lexicon Genetics has sublicensed aspects of its proprietary knockout mouse technology to Eli Lilly, the company announced Thursday.

The non-exclusive license covers the positive-negative selection and isogenic DNA technologies that Lexicon has licensed from academic researchers for its proprietary mouse gene function validation experiments.

Lilly plans to use the knockout mouse technology in its drug discovery and target validation research. The parties did not disclose the financial terms of the agreement.

" We are pleased that Lilly has joined our growing list of sublicensees for Lexicon's powerful gene-targeting technology," said Randall Riggs, Lexicon’s senior vice president of business development said in a statement. “It has become the gold standard for target validation."

Lexicon’s other sublicensees for this technology include Bristol-Myers Squibb, Pfizer, Roche Bioscience, Schering-Plough Research Institute, Millennium Pharmaceuticals, Genentech, Amgen, Ligand Pharmaceuticals, American Home Products, DuPont Pharmaceuticals, and Biogen.

This new agreement follows on the heels of rival Deltagen’s Monday announcement that it had filed an antitrust countersuit against Lexicon. Lexicon has sued Deltagen for patent infringement on positive-negative selection and its isogenic DNA technologies, and this suit is pending in federal court.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.